Do you offer systemic therapy for NSCLC (no driver mutation) after resection of a metachronous solitary brain metastasis occuring after definitive therapy for limited disease, with no evidence of active extracranial disease?  


Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Intermountain Healthcare
I generally agree with @Gregory A. Otterson, but w...
Medical Oncologist at Emory University School of Medicine
Would you follow same rationale that @Gregory A. O...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution